Works matching DE "MIGRAINE prevention"
Results: 880
Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: A case series.
- Published in:
- Proceedings of Singapore Healthcare, 2020, v. 29, n. 3, p. 212, doi. 10.1177/2010105820935465
- By:
- Publication type:
- Article
Burden of hidden migraine among the Arab general population: a cross-sectional study.
- Published in:
- Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-025-01974-9
- By:
- Publication type:
- Article
Network meta-analysis comparing efficacy of different strategies on medication-overuse headache.
- Published in:
- Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-025-01982-9
- By:
- Publication type:
- Article
Magnesium and Migraine.
- Published in:
- Nutrients, 2025, v. 17, n. 4, p. 725, doi. 10.3390/nu17040725
- By:
- Publication type:
- Article
Dietary Patterns and Migraine: Insights and Impact.
- Published in:
- Nutrients, 2025, v. 17, n. 4, p. 669, doi. 10.3390/nu17040669
- By:
- Publication type:
- Article
Adis Summary of Research: A retrospective real-life multicenter study on concurrent oral preventive treatments in patients with chronic migraine treated with onabotulinumtoxinA.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 12, p. 464, doi. 10.1007/s40267-024-01113-5
- By:
- Publication type:
- Article
Calcitonin gene-related peptide-targeted therapies are effective options for the prevention and treatment of migraine.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 6, p. 195, doi. 10.1007/s40267-023-00995-1
- By:
- Publication type:
- Article
Migraine Management in Women: Exploring the Impact of Combined Hormonal Contraceptives on Menstrual Migraine.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Beyond Birth Control: Noncontraceptive Benefits of Hormonal Methods and Their Key Role in the General Medical Care of Women.
- Published in:
- Journal of Women's Health (15409996), 2020, v. 29, n. 7, p. 937, doi. 10.1089/jwh.2019.7731
- By:
- Publication type:
- Article
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01448-2
- By:
- Publication type:
- Article
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01428-6
- By:
- Publication type:
- Article
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01433-9
- By:
- Publication type:
- Article
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01415-x
- By:
- Publication type:
- Article
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01413-z
- By:
- Publication type:
- Article
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01396-x
- By:
- Publication type:
- Article
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01418-8
- By:
- Publication type:
- Article
FKN/CX3CR1 axis facilitates migraine-Like behaviour by activating thalamic-cortical network microglia in status epilepticus model rats.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01416-w
- By:
- Publication type:
- Article
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01417-9
- By:
- Publication type:
- Article
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01387-y
- By:
- Publication type:
- Article
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-021-01376-7
- By:
- Publication type:
- Article
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-021-01374-9
- By:
- Publication type:
- Article
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01368-7
- By:
- Publication type:
- Article
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01366-9
- By:
- Publication type:
- Article
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01361-0
- By:
- Publication type:
- Article
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01360-1
- By:
- Publication type:
- Article
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01351-2
- By:
- Publication type:
- Article
Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01347-y
- By:
- Publication type:
- Article
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01344-1
- By:
- Publication type:
- Article
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01335-2
- By:
- Publication type:
- Article
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01337-0
- By:
- Publication type:
- Article
Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01322-7
- By:
- Publication type:
- Article
Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01316-5
- By:
- Publication type:
- Article
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01299-3
- By:
- Publication type:
- Article
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01267-x
- By:
- Publication type:
- Article
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01279-7
- By:
- Publication type:
- Article
InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01258-y
- By:
- Publication type:
- Article
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01234-6
- By:
- Publication type:
- Article
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01247-1
- By:
- Publication type:
- Article
Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01229-3
- By:
- Publication type:
- Article
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01215-9
- By:
- Publication type:
- Article
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01190-7
- By:
- Publication type:
- Article
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. N.PAG, doi. 10.1186/s10194-020-01186-3
- By:
- Publication type:
- Article
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. N.PAG, doi. 10.1186/s10194-020-01173-8
- By:
- Publication type:
- Article
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. N.PAG, doi. 10.1186/s10194-020-01177-4
- By:
- Publication type:
- Article
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01157-8
- By:
- Publication type:
- Article
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01148-9
- By:
- Publication type:
- Article